Over 70 Total Lots Up For Auction at One Location - FL 02/18

SimonMed Imaging to launch AI-enabled personalized breast cancer detection

Press releases may be edited for formatting or style | January 24, 2025 Women's Health
SCOTTSDALE, AZ, JAN 21, 2025 – SimonMed Imaging (“SimonMed”), one of the largest outpatient medical imaging providers and radiology practices in the United States, today announces its new AI enabled Personalized Breast Cancer Detection (PBCD) program now available to patients at SimonMed centers nationwide.

“SimonMed has offered AI technology in all 3D Mammograms to enhance breast cancer detection since 2019. Unlike other imaging centers, we offer this service at no additional cost to patients and will continue to do so,” said Dr. John Simon, CEO and Founder of SimonMed. “With PBCD, we're taking AI enhanced Mammogram screening a step further by offering patients the option to have a timely, personalized risk assessment that considers each patient's unique health profile. This comprehensive approach ensures that patients receive tailored recommendations for further screening, empowering them with the right care including ultrasound or MRI based on their individual risk levels. We know adding ultrasound or MRI to AI enhanced mammography with an individualized approach can more than double early detection. Our AI-driven platform is designed to help patients, and their healthcare providers, make more informed decisions, enhancing early detection and improving outcomes."

SimonMed is offering PBCD for $40 to be added to a screening 3D AI-enhanced mammogram, with no added radiation exposure or extra time. Patients will benefit from faster results, detailed breast density recommendations, a personal risk assessment and tailored action plan outlining screening cadence and supplement exams, helping patients and their doctors to make informed, proactive decisions about their breast health.

“The biggest improvement we have seen with using AI in our screenings is the confidence it brings to both radiologists and patients. AI has become a game-changer, providing significant patient benefits in screenings. Now with PBCD, we can continue to give patients the confidence they deserve in protecting their health,” said Dr. Angela Fried, MD, Director of Women’s Imaging at SimonMed.

This launch underscores SimonMed’s commitment to making AI-powered healthcare accessible and affordable. It is part of a broader initiative to bring advanced AI solutions to women’s health and beyond. For more details on SimonMed’s PBCD and how it can benefit patients, visit simonmed.com.


About SimonMed
Headquartered in Scottsdale, Arizona, SimonMed is one of the largest outpatient medical imaging providers and radiology practices in the United States. SimonMed has approximately 170 sites across 11 states and over 200 subspecialty-trained radiologists. SimonMed offers the full modality of diagnostic scans, including 3T MRI, CT, ultrasound, 3-D mammography, PET/CT, nuclear medicine, DEXA, X-rays, among others. The company uses the newest, most advanced, diagnostic imaging technologies while maintaining affordability and accessibility. SimonMed is a worldwide leader in the clinical use of AI to improve diagnoses with one of the largest global deployments to enhance early breast cancer detection and in the evaluation of brain disorders. Through its simonONE division, SimonMed is also at the forefront of personalized imaging for the early diagnosis and treatment of disease. For more information, visit simonone.com and simonmed.com.

Back to HCB News

You Must Be Logged In To Post A Comment